Developmental Funds

发展基金

基本信息

批准号：
10377477
负责人：
GUSTAVO Walter LEONE
金额：
$ 58.11万
依托单位：
MEDICAL UNIVERSITY OF SOUTH CAROLINA
依托单位国家：
美国
项目类别：
财政年份：
2009
资助国家：
美国
起止时间：
2009-04-01 至 2024-03-31
项目状态：
已结题

来源：
https://reporter.nih.gov/project-details/10377477
关键词：
Area Award Basic Science Biochemistry Biological Markers Cancer Biology Cancer Center Cancer Center Support Grant Catchment Area Cell Separation Cells Charge Clinical Clinical Investigator Clinical Research Cytometry Development Doctor of Philosophy Effectiveness Extramural Activities Faculty Faculty Recruitment Flow Cytometry Funding Grant Growth Immunology Investments Link Malignant Neoplasms Medical Microbiology Molecular Molecular Biology Pennsylvania Pharmacology Physicians Play Proteomics Research Research Personnel Research Support Resource Sharing Role Science Scientist Sorting - Cell Movement Source South Carolina Strategic Planning Technology Therapeutic Time Translational Research Universities anticancer research dimensional analysis high dimensionality high reward high risk innovation interdisciplinary collaboration investigator-initiated trial lipidomics meetings multidisciplinary pre-clinical professor programs recruit tumor immunology

项目摘要

DEVELOPMENTAL FUNDS: SUMMARY The Hollings Cancer Center (HCC) at the Medical University of South Carolina (MUSC) utilizes the Cancer Center Support Grant (CCSG) developmental funds to fuel its strategic plans for advancement of junior investigators, team science, translational and clinical research, and support of strategic faculty recruitments. During the current project period a total of $633,635 of CCSG developmental funds were distributed for pilot research funding in support of nine projects. Including the CCSG funds, HCC invested a total of $2.7 million in pilot research funds awarded between 2013-2018, which can be directly linked to the successful award of $26 million in extramural, multi-year grant funding. This is a nearly 10-fold yield from the investment of CCSG dollars. In addition, CCSG developmental funds supported the recruitment of three new faculty recruits supporting the expansion of scientific expertise in the Cancer Biology (CB), Developmental Cancer Therapeutics (DCT), and Cancer Immunology (CI) Programs. J. Alan Diehl, PhD and Professor of Biochemistry & Molecular Biology holds the SmartState Endowed Professor of Lipidomics and Pathobiology Chair. Diehl was recruited to MUSC in 2014 from the University of Pennsylvania to serve as the Associate Director of Basic Science. His research is currently funded by an NCI R01 and three NCI P01s. Anand Mehta, PhD and Professor of Cell & Molecular Pharmacology and SmartState Endowed Chair of Proteomic Biomarkers was recruited to MUSC in 2016 from Drexel University. Mehta’s research is currently funded by an NCI U01 and R01. Carsten Krieg, PhD is Assistant Professor of Microbiology & Immunology and recruited to MUSC in 2017 from the University of Zurich. His expertise in single cell cytometry by time of flight (CyTOF) was identified as a priority focal area for Cancer Immunology Program. Krieg is now building a technology platform within the HCC’s Flow Cytometry & Cell Sorting (FCCS) Shared Resource for high dimensional analysis using mass cytometry or conventional flow cytometers and high dimensional sorting for HCC investigators. In the next project period, the HCC requests $602,250 per year in developmental funds, 27% of the overall direct Cancer Center Support Grant request. These funds will be utilized in meeting the following specific aims: 1) Award pilot research funding to HCC investigators to promote team science, high risk/high reward ideas, and pre-clinical and clinical concepts; 2) Invest in new faculty start-up packages in support of the HCC six-year strategic plan; and 3) Support up to 20% effort for two early-stage clinical investigators annually who will be charged with developing innovative investigator-initiated trials.

发展基金：摘要南卡罗来纳医科大学 (MUSC) 的霍林斯癌症中心 (HCC) 利用癌症中心支持补助金 (CCSG) 发展基金，以推动其青少年发展战略计划研究人员、团队科学、转化和临床研究以及战略教师招聘的支持。在当前项目期间，CCSG 开发资金总计 633,635 美元用于试点包括 CCSG 基金在内，HCC 总共投资了 270 万美元，用于支持 9 个项目。 2013年至2018年间授予的试点研究基金，可直接与成功授予的26美元挂钩这相当于 CCSG 投资收益的近 10 倍。此外，CCSG 发展基金还支持招聘三名新教师。支持扩大癌症生物学 (CB)、发育性癌症方面的科学专业知识 J. Alan Diehl 博士和生物化学教授。与分子生物学担任 SmartState 脂质组学和病理生物学教授 Diehl 主席。 2014年从宾夕法尼亚大学被招募到MUSC，担任基础系副主任他的研究目前由一名 NCI R01 和三名 NCI P01 博士资助。细胞与分子药理学教授和 SmartState 赋予的蛋白质组生物标志物主席 Mehta 于 2016 年从德雷克塞尔大学招募到 MUSC，其研究目前由 NCI U01 和 NCI U01 资助。 R01. Carsten Krieg 博士是微生物学和免疫学助理教授，于 2017 年被聘为 MUSC 他在苏黎世大学获得了飞行时间单细胞细胞术 (CyTOF) 方面的专业知识，被认为是癌症免疫学计划的优先重点领域目前正在建立一个技术平台。 HCC 的流式细胞术和细胞分选 (FCCS) 共享资源，用于使用质量进行高维分析细胞计数或传统流式细胞仪以及 HCC 研究人员的高维分选。项目期间，HCC 每年请求 602,250 美元的发展资金，占直接癌症总额的 27% 中心支持拨款请求。这些资金将用于实现以下具体目标：1）奖励试点。为 HCC 研究人员提供研究经费，以促进团队科学、高风险/高回报理念和临床前研究和临床概念；2) 投资新的教师启动计划，以支持 HCC 六年战略计划； 3) 每年为两名早期临床研究人员提供高达 20% 的支持，他们将负责开发由研究者发起的创新试验。